These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 30931812)
1. Clinical features and treatment of patients with lung adenocarcinoma with bone marrow metastasis. Wang D; Luo Y; Shen D; Yang L; Liu HY; Che YQ Tumori; 2019 Oct; 105(5):388-393. PubMed ID: 30931812 [TBL] [Abstract][Full Text] [Related]
2. Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma. Feng LX; Wang J; Yu Z; Song SA; Zhai WX; Dong SH; Yu HS; Zhang Y Clin Transl Oncol; 2019 Aug; 21(8):1005-1013. PubMed ID: 30637712 [TBL] [Abstract][Full Text] [Related]
3. Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma. Chen HJ; Tu CY; Huang KY; Chien CR; Hsia TC PLoS One; 2020; 15(12):e0240736. PubMed ID: 33306683 [TBL] [Abstract][Full Text] [Related]
4. [Clinical Analysis of Small Cell Lung Cancer with Bone Marrow Metastases]. Che Y; Luo Y; Wang D; Shen D; Yang L Zhongguo Fei Ai Za Zhi; 2018 May; 21(5):403-407. PubMed ID: 29764591 [TBL] [Abstract][Full Text] [Related]
5. Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor. Kwon BS; Cho YH; Yoon SK; Lee DH; Kim SW; Kwon DH; Lee JC; Choi CM Thorac Cancer; 2020 Feb; 11(2):436-442. PubMed ID: 31910497 [TBL] [Abstract][Full Text] [Related]
6. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328 [TBL] [Abstract][Full Text] [Related]
7. Correlation between efficacy of the EGFR tyrosine kinase inhibitor and serum tumor markers in lung adenocarcinoma patients. Pan JB; Hou YH; Zhang GJ Clin Lab; 2014; 60(9):1439-47. PubMed ID: 25291939 [TBL] [Abstract][Full Text] [Related]
8. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma. Li H; Wang Y; Su F; Li J; Gong P Int J Clin Exp Pathol; 2015; 8(5):5577-83. PubMed ID: 26191267 [TBL] [Abstract][Full Text] [Related]
9. [Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis]. Chen L; Fu M; Zhou J; Yao Y; Zhou J Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):312-318. PubMed ID: 31109441 [TBL] [Abstract][Full Text] [Related]
10. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma. Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717 [TBL] [Abstract][Full Text] [Related]
12. Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations. Gao Y; Song P; Li H; Jia H; Zhang B BMC Cancer; 2017 Jul; 17(1):484. PubMed ID: 28705152 [TBL] [Abstract][Full Text] [Related]
13. Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations. Nagata M; Kudoh S; Mitsuoka S; Suzumura T; Umekawa K; Tanaka H; Matsuura K; Kimura T; Yoshimura N; Hirata K Osaka City Med J; 2013 Jun; 59(1):45-52. PubMed ID: 23909080 [TBL] [Abstract][Full Text] [Related]
14. Lactate dehydrogenase and serum tumor markers for predicting metastatic status in geriatric patients with lung adenocarcinoma. Ren X; Zhang Y; Lyu Y; Jin B; Guo H; Wu J; Li X; Liu X Cancer Biomark; 2019; 26(2):139-150. PubMed ID: 31356196 [TBL] [Abstract][Full Text] [Related]
15. Chemotherapy should be performed in epidermal growth factor receptor mutation-positive lung adenocarcinoma patients who had progressive disease to the first epidermal growth factor receptor-tyrosine kinase inhibitor. Kashiwabara K; Fujii S; Tsumura S; Sakamoto K Anticancer Drugs; 2020 Oct; 31(9):959-965. PubMed ID: 32889898 [TBL] [Abstract][Full Text] [Related]
16. Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients. Hu F; Li C; Xu J; Guo J; Shen Y; Nie W; Zheng X; Wang L; Zhang H; Han B; Zhang X Lung Cancer; 2019 Sep; 135():138-144. PubMed ID: 31446986 [TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of gastric cancer patients with bone marrow metastases. Kim HS; Yi SY; Jun HJ; Lee J; Park JO; Park YS; Jang J; Kim HJ; Ko Y; Lim HY; Kang WK Oncology; 2007; 73(3-4):192-7. PubMed ID: 18418012 [TBL] [Abstract][Full Text] [Related]
18. Analysis of Progression Patterns and Failure Sites of Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Receiving First-line Treatment of Tyrosine Kinase Inhibitors. Li XY; Zhu XR; Zhang CC; Yu W; Zhang B; Shen TL; Zhang HY; Fu XL Clin Lung Cancer; 2020 Nov; 21(6):534-544. PubMed ID: 32505632 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases. Ke SB; Qiu H; Chen JM; Shi W; Chen YS Curr Med Sci; 2018 Dec; 38(6):1062-1068. PubMed ID: 30536070 [TBL] [Abstract][Full Text] [Related]
20. Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique. Gu Y; Xu Y; Zhuang H; Jiang W; Zhang H; Li X; Liu Y; Ma L; Zhao D; Cheng Y; Yu Y; Liu P; Qin J; Chen X; Gao J; Wang M; Liang L; Cao B Thorac Cancer; 2021 Dec; 12(23):3157-3168. PubMed ID: 34651449 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]